News & Updates

Waitlisted registrants for liver transplantation (LT) who have nonalcoholic steatohepatitis (NASH) cirrhosis have a lower chance to receive a new organ and greater risk of waitlist mortality at 90 days and 1 year than patients with non-NASH cirrhosis, suggest the results of a Singapore study.

The selective farnesoid-X receptor agonist obeticholic acid appears to improve symptoms of low phospholipid-associated cholelithiasis (LPAC) syndrome in patients who have inadequate response or intolerance to ursodeoxycholic acid, as shown in a small study.

In the treatment of patients with nonalcoholic steatohepatitis (NASH), the glycoPEGylated FGF21 analogue pegozafermin appears to confer beneficial effects on hepatic and metabolic parameters while being well tolerated, according to the results of a phase 1b/2a clinical trial.

Treatment with 5-methyltetrahydrofolate (5-MTHF) significantly enhances the effect of propranolol in reducing hepatic venous pressure gradient (HVPG) in patients with cirrhosis and portal hypertension, a recent study has shown.

The combination of hepatocyte-derived biomarkers and FibroTest or model for end-stage liver disease (MELD) scores can help identify patients with Child-Pugh class A alcohol-related cirrhosis who are prone to liver-related events at 2 years, reports a study.